该联合治疗通过诱导肿瘤细胞发生 ICD，激活 IFN-γ 和 NF-κB 信号通路，进而增强 CCL2/8 - CCR2 轴和 CXCL9/10 - CXCR3 轴，招募 CD8 + T 细胞和 CD4 + T 细胞浸润，发挥抗肿瘤作用。CCL2/8 - CCR2 和 CXCL9/10 - CXCR3 有望成为预测 NSCLC 患者对 TTFields 联合抗 PD 疗法响应的潜在生物标志 ...

Ivonescimab Targeting 2nd-Lin EGFR-Mutant Non-Small Cell Lung Cancer Patients As I stated above, Summit Therapeutics is gearing up to release top-line data from its ongoing phase 3 HARMONi study ...